Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon in REM Behavior Disorder
NCT05922995Phase 1Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tasimelteon in REM sleep behavior disorder (RBD), sponsored by Brigham and Women's Hospital. Primary endpoints: Daily Sleep Diary - Visual Fill-In at 8 weeks, Daily Sleep Diary - Time Keeping at 8 weeks and 2 more. Started Sep 2023; status: terminated.
02
Drugs
tasimelteon
03
Conditions
REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT05922995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922995.